Investing in biotech and pharmaceuticals is always a bit of a wild card. The industry is often at the mercy of government regulators, and a clinical trial can always present unexpected challenges. When biotech and pharma stocks hit it big, however, its big news that often yields big returns. A lesser promoted biotech sector is the medical devices arena, which is hardly as sexy and....More>>>
Click to enlarge
Sarepta’s hearings. Or how to get a drug approved on emotional grounds. Source: Boston Globe.
In the world of biotech, amazing things sometimes happen. This article is about one such amazing thing: Sarepta’s (NASDAQ:SRPT) twin sister drug, company and stock.
The twin sister, of course, is AveXis (NASDAQ:AVXS). Consider the following:
Billionaire investor Warren Buffett was a sharp critic of Donald Trump during the presidential campaign, but said in an interview broadcast by CNN Friday that he expects the stock market to continue rising.
The stock market will be higher 10, 20 and 30 years from now and it would have been with Hillary [Clinton] and it will be with Trump, Buffett said. Suggestions by market pundits that stocks....More>>>
Some analysts cite Hillary Clinton’s continued criticism of drug prices as a cause for a slump in biotech during the U.S. presidential campaign, but with the election behind us, many biotech enterprises saw at least a 9% increase due to Donald Trump’s victory.
Two companies in the biotech space entering the first quarter of 2017 may be in a position for their products, as well....More>>>
On Thursday, our Elite Opportunity Pronewsletter suggested getting into Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA: LABU) in part totake advantage of the January effect:
As a matter of fact, the entire biotech sector was the big performer yesterday, so we’re going to go ahead and take another shot with LABU, one of the primary bullish leveraged ETF’s tracking the....More>>>
Shares of Inovio Pharmaceuticals(INO) are climbing today after the biotech company announced that it would begin testing a Zika vaccine in Puerto Rico. Maxim’sJason McCarthy andJason Kolbert have the details:
CREDIT: Alex Wild Published Credit: Alex Wild Alex Wild
Inovio announced the initiation of a small clinical study (N=160) of its Zika vaccine, GLS-5700 (being developed....More>>>
If you're not profiting from the "Melt Up" yet, what are you waiting for? You're running out of time… Stocks aren't going to go up forever. My Melt Up theme is the idea that stocks tend to soar in the final months of a great bull market as it comes to an end. And we're entering that time – right now. The end of the dot-com boom in 2000....More>>>
Welcome to another edition of “3 Things in Biotech You Should Learn Today,” a daily digest dedicated to helping you keep tabs on the fast-moving world of biotech and pharmaceutical research.
Let’s get started!
AstraZeneca whiplash continues with more durvalumab news
In a scrambling defense of disappointing MYSTIC results for its immune checkpoint inhibitor....More>>>
U.S. stocks reversed direction to close mostly lower Thursday as weak financials and consumer staples shares eclipsed a rally in the health-care and biotechnology sectors.
The S&P 500 ....More>>>
March has been a month associated with bad news. Remember Julius Caesar and the ides of March? At least Julius had the opportunity to enjoy a couple of good weeks before disaster struck.
Bad news came early in the month for Juno Therapeutics (NASDAQ:JUNO) and PTC Therapeutics (NASDAQ:PTCT). Both companies announced major pipeline setbacks. What’s next for these beleaguered biotechs?
Welcome to another edition of “3 Things In Biotech You Should Learn Today,” a daily digest dedicated to helping you keep up with recent events in the biotech and pharmaceutical industries!
So what’s in store for today?
BioMarin makes itself a priority to the FDA in phenylketonuria
Phenylketonuria is a congenital disorder that can lead to severe complications....More>>>
ImmunoGen (NASDAQ:IMGN) is up 15.6% at 3:35 p.m. EDT on no news. The stock price bump might be a carryover from yesterday’s upgrade by Leerink Partners. Or maybe it’s short-sellers buying to cover their shorts after yesterday’s move. Or maybe it’s just because it’s a biotech and the sun came up today. Who knows?
We are coming into the fall and the third quarter, aftera surprisingly solid push fromthe markets over the summer. Analysts may say it isnt fundamentally sound but that does not detract from the gains. The high valuations, low volatility, no sell in May and go away and even weak economic data and earnings seem immaterial at this point.
The bull market is now over seven years old. Still, the....More>>>
Struggling to find an acceptable return in this low rate environment? Need more safe healthcare exposure to ballast against the recent pullback in all things biotech-related?
Despite not paying dividends before 2011, Amgen (NASDAQ:AMGN) has since quadrupled its payout and may be just the stock you are looking for.
Let’s take a look at Amgen and see if this....More>>>
Donald Trump’s comments yesterday about the drug industry when he stated that drug companies were “getting away with murder” tanked biotech stocks and the general indexes. Investors in this space must be worried in the event that Trump gains some traction in this sector and records some wins. At present, he is like a dog with a bone. In the automotive sector, for example, he is....More>>>